PHVS

Conviction 41HealthcareScan · Thu, Sep 24, 2026

Pharvaris N.V. (PHVS) closed at $32.97 (-0.32%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 35, RS Rating 79, -15.2% from its 52-week high, +24.5% year to date. Sector: Healthcare · Biotechnology.

PHVS$32.97-0.32%

ResistanceSupportVol 14Insider sell

Vol MA14 1.34M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Pharvaris N.V.Biotechnologywww.pharvaris.com ↗

Price32.97

Change-0.32%

Gap-0.44%

Rel volume0.57×

Avg volume1.08M

Avg $ vol40.23M

SMA 2036.26

SMA 5035.32

SMA 20030.23

Price vs 50-6.67%

Price vs 200+9.05%

MA stackmixed

50/200 cross—

Supertrenddown · 38.88

RSI (14)35

MACD hist-0.57

MACD crossbear · 4d

Stoch %K / %D9 / 8

ADX (14)28

+DI / −DI20 / 25

RSI divergence—

MACD divergenceBearish

ATR %6.03%

ADR %5.50%

52w high38.86

52w low20.96

From 52w high-15.17%

Above 52w low+57.28%

New 52w highNo

SqueezeOff

Bollinger width18.25%

%B0.00

Donchian pos8.98%

Donchian high43.25

Donchian low31.95

AVWAP (52w high)38.19

vs AVWAP high-13.68%

AVWAP (52w low)31.87

vs AVWAP low+3.43%

OBV trendFlat

Chaikin MF (20)-0.55

Today vs 20d0.57×

Avg vol (14d)1.34M

Avg vol (20d)1.08M

Avg $ vol (20d)40.23M

Market cap2.15B

RS Rating79 / 99

RS 3m (vs SPY)-5.50%

RS 6m (vs SPY)+9.24%

RS line new highNo

Trend template6/8

Technical rank56.9

1 week-13.25%

1 month-11.46%

3 months-1.01%

6 months+26.06%

1 year+32.39%

YTD+24.49%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target61.33

Target upside86.05%

Analyst ratingBuy

Institutional92.51%

Ent. value2.15B

Revenue—

Net income—

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees129

ListedFri, Feb 5, 2021

Free float44.23M

Float %63.0%

Short interest2.16M

Days to cover3.4d

Short volume32.0%

Squeeze score27 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.81 vs −$0.74

Last surprise-9.5% miss

Setup gradeD

Conviction41 / 100

Pattern quality—

Tech rank56.9 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance41.93

Support32.26

Days since event—

Candle confirm—

Congress activity

Disclosed STOCK Act trades in PHVS

All disclosures →

No recent disclosed trades by Congress in PHVS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in PHVS · open-market 3 sells

Insider	Side	Shares	Value	Traded	Filed
Bjork Elisabeth Director · Common Stock · 2026-09-17	Exercise	17.5K	$317K	2026-09-17	2026-09-21
Bjork Elisabeth Director · Common Stock · 2026-09-17	Exercise	35K	$504K	2026-09-17	2026-09-21
Bjork Elisabeth Director · Common Stock · 2026-09-17	Sell	52.5K	$2.0M	2026-09-17	2026-09-21
Bjork Elisabeth Director · Stock Option (Right to Buy) · 2026-09-17	Exercise	35K	—	2026-09-17	2026-09-21
Bjork Elisabeth Director · Stock Option (Right to Buy) · 2026-09-17	Exercise	17.5K	—	2026-09-17	2026-09-21
Glassman Robert Director · Common Stock · 2026-09-17	Exercise	14.49K	$263K	2026-09-17	2026-09-21
Glassman Robert Director · Common Stock · 2026-09-17	Sell	14.49K	$559K	2026-09-17	2026-09-21
Glassman Robert Director · Stock Option (Right to Buy) · 2026-09-17	Exercise	14.49K	—	2026-09-17	2026-09-21
Lesage Anne Chief Early Development · Common Stock · 2026-09-17	Sell	20K	$765K	2026-09-17	2026-09-21
Lu Peng President · Common Stock · 2026-09-17	Exercise	100K	$259K	2026-09-17	2026-09-21

SEC filings

EDGAR filings in PHVS · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.